FR2184934B1 - - Google Patents

Info

Publication number
FR2184934B1
FR2184934B1 FR7317756A FR7317756A FR2184934B1 FR 2184934 B1 FR2184934 B1 FR 2184934B1 FR 7317756 A FR7317756 A FR 7317756A FR 7317756 A FR7317756 A FR 7317756A FR 2184934 B1 FR2184934 B1 FR 2184934B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7317756A
Other languages
French (fr)
Other versions
FR2184934A1 (OSRAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AH Robins Co Inc
Original Assignee
AH Robins Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AH Robins Co Inc filed Critical AH Robins Co Inc
Publication of FR2184934A1 publication Critical patent/FR2184934A1/fr
Application granted granted Critical
Publication of FR2184934B1 publication Critical patent/FR2184934B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7317756A 1975-08-13 1973-05-16 Expired FR2184934B1 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/604,371 US4045576A (en) 1975-08-13 1975-08-13 Anti-inflammatory methods using 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof and the compounds

Publications (2)

Publication Number Publication Date
FR2184934A1 FR2184934A1 (OSRAM) 1973-12-28
FR2184934B1 true FR2184934B1 (OSRAM) 1976-11-05

Family

ID=24419335

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7317756A Expired FR2184934B1 (OSRAM) 1975-08-13 1973-05-16

Country Status (15)

Country Link
US (3) US4045576A (OSRAM)
JP (3) JPS523381B2 (OSRAM)
AT (2) AT329542B (OSRAM)
AU (1) AU530940B2 (OSRAM)
BE (2) BE799611A (OSRAM)
CA (2) CA1012979A (OSRAM)
CH (1) CH577461A5 (OSRAM)
DE (2) DE2324768C2 (OSRAM)
ES (1) ES446625A1 (OSRAM)
FR (1) FR2184934B1 (OSRAM)
GB (2) GB1432576A (OSRAM)
MX (1) MX4035E (OSRAM)
NL (1) NL183722C (OSRAM)
PH (2) PH12656A (OSRAM)
SE (1) SE400966B (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
FR2366015A1 (fr) * 1975-11-05 1978-04-28 Robins Co Inc A H Nouveaux acides amino-2 benzoyl-3 (5 et 6) phenylacetiques et leurs esters et sels de metaux alcalins, utiles notamment comme anti-inflammatoires, et leur procede de preparation
US4221716A (en) * 1979-02-16 1980-09-09 A. H. Robins Company, Inc. Intermediate and process for the preparation of 7-acylindolin-2-ones
EP0089426B1 (en) * 1979-07-12 1986-06-11 A.H. Robins Company, Incorporated 2-amino-6-biphenylacetic acids
IL60444A (en) * 1979-08-01 1985-03-31 Robins Co Inc A H 2-amino-3-(alkylthiobenzoyl)-phenylacetic acid derivatives and pharmaceutical compositions containing them
ZA805476B (en) * 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
US4503073A (en) * 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
JPS6019753A (ja) * 1983-07-13 1985-01-31 Shionogi & Co Ltd オルト−（モノ置換アミノ）フエニルイミン類およびその製造法
JPS6026586U (ja) * 1983-07-29 1985-02-22 日本軽金属株式会社 改装サッシ窓における隙間閉塞装置
SE8400239D0 (sv) * 1984-01-19 1984-01-19 Pharmacia Ab Nya arylettiksyraderivat
US4683242A (en) * 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
US4782089A (en) * 1986-08-26 1988-11-01 A. H. Robins Company, Incorporated 2-amino-3-aroyl-gamma-oxobenzenebutanoic acids and esters
US4880788A (en) * 1987-10-30 1989-11-14 Baylor College Of Medicine Method for preventing and treating thrombosis
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US5179119A (en) * 1989-08-02 1993-01-12 Hoechst-Roussel Pharmaceuticals Incorporated 1,3-dihydro-1-(pyridinylamino)-2H-indol-1-ones and intermediates for the preparation thereof
AU659106B2 (en) * 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted phenyl and pyridyl amino carboxylates
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
KR20010012131A (ko) * 1997-04-28 2001-02-15 가부시키가이샤 이가쿠죠호서비스 케토프로펜 및 5-벤조일-3-메틸-2-인돌리논의 제조방법
AR030345A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
WO2002070478A1 (en) * 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
AU2002247284A1 (en) 2001-04-02 2002-10-15 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
US6692772B2 (en) 2001-07-18 2004-02-17 Cedars-Sinai Medical Center Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium
MXPA04010132A (es) * 2002-05-03 2005-01-25 Alcon Inc Metodo para tratar trastornos vasculares mediados por el factor de crecimiento endotelial vascular.
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
JP2010522690A (ja) * 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
MX2009003875A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados y compuestos relacionados de espiro(furo[3,2-c]piridina- 3,3'-indol)-2' (1'h)ona para el tratamiento de enfermedades mediadas por los canales de sodio, tal como dolor.
MX2009003876A (es) * 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2008046083A2 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US20090076150A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched bromfenac
JP2011513229A (ja) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド 補助剤としての眼科用ｎｓａｉｄ
PT2350090E (pt) * 2008-10-17 2015-11-13 Xenon Pharmaceuticals Inc Composto espiro-oxindol e suas utilizações como agentes terapêuticos
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
PE20121350A1 (es) 2009-10-14 2012-10-20 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
KR101854946B1 (ko) * 2010-12-21 2018-05-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 2-(트리아지닐카르보닐) 술폰아닐리드의 제조 방법
US20140142182A1 (en) 2012-11-19 2014-05-22 Bausch & Lomb Incorporated Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid
CA2911983A1 (en) 2013-06-19 2014-12-24 Sentiss Research Center Stable bromfenac solution
US20170000889A1 (en) 2013-12-12 2017-01-05 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104974057B (zh) * 2014-04-08 2018-05-18 天津金耀集团有限公司 一种溴芬酸钠的制备方法和重要中间体
CN104151182B (zh) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 一种溴芬酸钠倍半水合物的制备方法
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
CN104693019B (zh) * 2015-02-06 2017-02-01 宁波九胜创新医药科技有限公司 一种2,5‑二溴苯乙酸的制备方法
CN106278918B (zh) * 2016-08-12 2018-05-11 合肥久诺医药科技有限公司 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法
CN106278917B (zh) * 2016-08-12 2018-05-08 合肥久诺医药科技有限公司 一种溴芬酸钠降解杂质标准品的合成方法
WO2019004352A1 (ja) 2017-06-30 2019-01-03 株式会社クラレ 変性ポリビニルアルコール樹脂の製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (OSRAM) * 1967-07-31 1971-03-24
US3899529A (en) * 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
SE400966B (sv) * 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror

Also Published As

Publication number Publication date
CA1087205A (en) 1980-10-07
AU6181480A (en) 1981-01-08
BE837154A (fr) 1976-04-16
ATA429873A (de) 1975-08-15
PH15112A (en) 1982-08-10
AT347433B (de) 1978-12-27
ES446625A1 (es) 1977-06-01
SE400966B (sv) 1978-04-17
FR2184934A1 (OSRAM) 1973-12-28
US4045576A (en) 1977-08-30
BE799611A (fr) 1973-09-17
DE2324768A1 (de) 1973-11-29
JPS5223052A (en) 1977-02-21
US4182774A (en) 1980-01-08
JPS4941349A (OSRAM) 1974-04-18
US4126635A (en) 1978-11-21
AU530940B2 (en) 1983-08-04
PH12656A (en) 1979-07-11
GB1432576A (en) 1976-04-22
AU5584673A (en) 1974-11-21
AT329542B (de) 1976-05-10
JPS523381B2 (OSRAM) 1977-01-27
JPS55349A (en) 1980-01-05
MX4035E (es) 1981-11-18
CA1012979A (en) 1977-06-28
DE2324768C2 (de) 1985-08-14
ATA977475A (de) 1978-05-15
NL183722C (nl) 1989-01-02
CH577461A5 (OSRAM) 1976-07-15
NL7306833A (OSRAM) 1973-11-20
DE2636582A1 (de) 1977-02-24
JPS5726585B2 (OSRAM) 1982-06-05
DE2636582C2 (de) 1986-03-27
NL183722B (nl) 1988-08-01
GB1521097A (en) 1978-08-09

Similar Documents

Publication Publication Date Title
AR201758A1 (OSRAM)
AU465372B2 (OSRAM)
FR2184934B1 (OSRAM)
AU474593B2 (OSRAM)
AU474511B2 (OSRAM)
AU465453B2 (OSRAM)
AU471343B2 (OSRAM)
AU465434B2 (OSRAM)
AU450229B2 (OSRAM)
AU466283B2 (OSRAM)
AU472848B2 (OSRAM)
AU477824B2 (OSRAM)
AU471461B2 (OSRAM)
AR200885A1 (OSRAM)
AR201432A1 (OSRAM)
AU461342B2 (OSRAM)
AU447540B2 (OSRAM)
AR200256A1 (OSRAM)
AR210729A1 (OSRAM)
AU1891376A (OSRAM)
CH564324A5 (OSRAM)
AU479562A (OSRAM)
CH563549A5 (OSRAM)
CH563136A5 (OSRAM)
CH560299A5 (OSRAM)

Legal Events

Date Code Title Description
TP Transmission of property